Hanmi Drugs Show Promise in Phase 1 Trials
Hanmi Pharmaceutical said two next-generation anticancer drug candidates under development demonstrated both antitumor activity and safety in global Phase 1 clinical trials. The data, disclosed at the ESMO Congress 2026 held in Madrid, Spain, from on Oct. 23 to 27, provide specific clinical evidence
Hanmi Pharmaceutical's next-generation anticancer drugs, HM97662 and BH3120, showed promise in Phase 1 clinical trials, according to data presented at the ESMO Congress 2026 in Madrid, Spain. HM97662 uses a dual-inhibition approach targeting EZH1 and EZH2 proteins to suppress gene expression, overcoming resistance that can arise from inhibiting only EZH2.
The trial revealed a manageable safety profile and notable antitumor activity in specific mutation groups, including ovarian clear cell carcinoma, chordoma, mesothelioma, and uterine sarcoma. BH3120, an immuno-oncology candidate, employs a bispecific antibody platform to target cancer cells and activate immune cells, potentially expanding treatment to various solid tumors.
With favorable liver toxicity results, the drug showed positive safety in a dose-escalation study involving 45 patients. Hanmi Pharmaceutical plans to conduct further evaluations in an upcoming dose-expansion stage.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.